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Abstract
Background: Esophagectomy is considered the gold standard for the treatment of high-grade
dysplasia in Barrett's esophagus (BE) and for noninvasive adenocarcinoma (ACA) of the distal
esophagus. If all of the metaplastic epithelium is removed, the patient is considered "cured". Despite
this, BE has been reported in patients who have previously undergone esophagectomy. It is often
debated whether this is "new" BE or the result of an esophagectomy that did not include a
sufficiently proximal margin. Our aim was to determine if BE recurred in esophagectomy patients
where the entire segment of BE had been removed.
Methods: Records were searched for patients who had undergone esophagectomy for cure at our
institution. Records were reviewed for surgical, endoscopic, and histopathologic findings. The
patients in whom we have endoscopic follow-up are the subjects of this report.
Results: Since 1995, 45 patients have undergone esophagectomy for cure for Barrett's dysplasia
or localized ACA. Thirty-six of these 45 patients underwent endoscopy after surgery including 8/
45 patients (18%) with recurrent Barrett's metaplasia or neoplasia after curative resection.
Conclusion:  Recurrent Barrett's esophagus or adenocarcinoma after esophagectomy was
common in our patients who underwent at least one endoscopy after surgery. This appears to
represent the development of metachronous disease after complete resection of esophageal
disease. Half of these patients have required subsequent treatment thus far, either repeat surgery
or photodynamic therapy. These results support the use of endoscopic surveillance in patients who
have undergone "curative" esophagectomy for Barrett's dysplasia or localized cancer.
Background
The incidence of esophageal adenocarcinoma has
increased more rapidly than any other form of cancer
since the 1970s and now represents the majority of
esophageal neoplasms in the West [1]. Barrett's esophagus
is the replacement of native squamous mucosa by special-
ized intestinal metaplasia and is known to be the major
risk factor for the development of adenocarcinoma via the
metaplasia-dysplasia-neoplasia sequence [2]. Other risk
factors for the development of esophageal adenocarci-
noma include a lengthy and severe history of gastro-
esophageal reflux disease (GERD), increased body mass
index, male gender and Caucasian race [3-5]. Recent stud-
ies, however, have detected Barrett's esophagus in nearly
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equal numbers of older white men whether or not they
reported GERD symptoms [6,7]. Recommendations,
therefore, regarding screening and surveillance of patients
at risk for esophageal adenocarcinoma are controversial
[2,8].
Detection of dysplastic Barrett's esophagus or mucosal
adenocarcinoma is important because it allows the oppor-
tunity to intervene prior to the development of invasive
neoplasia. Unfortunately, no medical or surgical GERD
treatment has been consistently and convincingly demon-
strated to prevent the development of adenocarcinoma
[5]. Traditionally, high grade Barrett's dysplasia and
mucosal adenocarcinoma are treated by surgical resection
of the esophagus [9]. As endoscopic methods of screening
and surveillance have become more widely applied, cura-
tive esophagectomy has produced increasing numbers of
long-term survivors [10,11]. Coincident with this trend
has been the appearance of several reports describing the
development of metachronous esophageal adenocarci-
noma after undergoing curative esophagectomy for the
primary tumor [12,13]. These reports raise questions
regarding the role of endoscopic surveillance in these
patients. The aim of the current study was to evaluate
patients who had undergone complete, presumably cura-
tive, esophageal resection for early Barrett's adenocarci-
noma or high grade dysplasia in order to determine how
frequently, and over what time period, they developed
recurrent Barrett's esophagus or adenocarcinoma.
Methods
After approval by the Mayo Foundation's Institutional
Review Board for Research, the electronic medical records
of Mayo Clinic patients in Jacksonville, Florida, were
searched to find all patients who had undergone
esophagectomy for cure at the Mayo Clinic surgical facil-
ity, St. Luke's Hospital, Jacksonville, Florida, since 1995.
This time period was chosen to coincide with the routine
availability and clinical use of pre-operative staging with
endosonography in our institution. The records of these
patients were reviewed for pre-operative and post-opera-
tive staging results including computed tomography and
endosonography studies. In addition, endoscopic, surgi-
cal studies and histopathological studies were studied.
Specifically, the surgical specimens were reviewed to
ensure that the esophagectomy specimen, including
lymph node sampling, was adequate and the proximal
margin was completely free of Barrett's metaplasia, dys-
plasia or carcinoma. The patients, in whom we have at
least one follow-up endoscopy study, with biopsies
obtained for histologic confirmation of mucosal disease,
are the subjects of this report. Esophageal disease was
staged according to the Tumor-Lymph node-Metastasis
(TNM) criteria [14].
Results
Since 1995, 45 patients have undergone esophagectomy
for Barrett's dysplasia or localized adenocarcinoma with
curative intent in our institution. At operation, none of
these patients were found to have extension of malignant
disease to paraesophageal lymph nodes and all esopha-
geal glandular mucosa was resected with only normal
squamous mucosa remaining at the proximal surgical
margin. Subsequently, 36 of these patients (80%) have
undergone endoscopy after surgery including 8/45
patients (18%) who were found to have recurrent Barrett's
glandular mucosa after curative resection and are
described in the table.
Open transthoracic esophagectomy (Ivor Lewis proce-
dure) with pyloroplasty was performed in most patients
(39/45) including the patients diagnosed with recurrent
Barrett's disease. Five different surgeons performed these
operations. Most patients had evidence of gastric stasis
(retained food) at endoscopy (30/36; 83%). Anastomotic
dilation was performed at endoscopy in 16/36 patients
(range of dilation procedures 1–10; median 3). It is possi-
ble that patients with anastomotic strictures may be at
increased risk of recurrent Barrett's esophagus because of
worse reflux although their swallowing symptoms may,
alternatively, be related to other factors such as anasto-
motic ischemia or surgical sutures. Patients frequently
used aspirin (42%) or COX-2 specific non-steroidal anti-
inflammatory agents (25%). Twice-daily proton pump
inhibitors were routinely prescribed for these patients
although patient compliance is difficult to assess because
of high drug costs and limited symptomatic improve-
ment. While the small number of patients limits our anal-
ysis, these factors were found to occur in a proportional
number of patients with Barrett's disease and no clear
trends could be identified.
Five of these patients have been diagnosed with Barrett's
metaplasia or low-grade dysplasia have been followed for
more than 12 months in surveillance endoscopy pro-
grams monitoring the stability of the glandular epithe-
lium. Two of these 5 patients have been found to have
short segment Barrett's metaplasia with lengths of 10 mm
and 15 mm, after complete esophageal resection for Bar-
rett's high-grade dysplasia in a 72-year-old man and Bar-
rett's adenocarcinoma T2N0M0 in a 78-year-old man. This
metaplastic glandular epithelium was detected at a follow
up of 90 months and 17 months, respectively. In the other
3 patients, short segment Barrett's low-grade dysplasia has
been found in lengths between 10–25 mm after complete
resection of the esophagus for Barrett's high-grade dyspla-
sia (1 patient) and Barrett's T3N0M0  carcinoma (2
patients). This recurrent Barrett's glandular dysplasia was
detected at a follow up of 42–47 months. Erosive
esophagitis was also noted in 4 of 5 patients indicatingBMC Gastroenterology 2004, 4:18 http://www.biomedcentral.com/1471-230X/4/18
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uncontrolled reflux disease. Subsequently all patients
have been treated with high doses of proton pump inhib-
itors (such as esomeprazole 80 mg twice a day or 40 mg
three or four times per day) in an attempt to maximally
control reflux of acid and digestive juices from the stom-
ach into the cervical esophagus.
Three other patients developed recurrent Barrett's disease
after curative resection of esophageal T2 or T3N0M0 adeno-
carcinoma. These patients varied in age from 58–80 years
of age. These patients were found to have more severe ero-
sive esophagitis suggesting worse acid reflux and mucosal
injury compared to the non-carcinoma recurrent Barrett's
patients. Recurrent Barrett's multi-focal high-grade dys-
plasia, over a 10 mm segment length was detected 88
months after esophagectomy in one patient and was suc-
cessfully ablated with porfimer sodium photodynamic
therapy using the methods described elsewhere [15].
High-grade dysplasia with features of invasive adenocarci-
noma was noted in a 20 mm Barrett's segment diagnosed
18 months after esophageal resection in another patient.
Endosonography detected focal mucosal expansion and
the Barrett's mucosal adenocarcinoma T1N0M0 was con-
firmed at repeat esophagectomy. Finally, a diminutive
polypoid mass proximal to the surgical anastomosis was
found in a 58-year-old woman who had 7 months previ-
ously undergone esophagectomy for Barrett's mucosal
adenocarcinoma. Computed tomography with contrast
enhancement noted esophageal wall thickening and sus-
picious lymphadenopathy. Repeat resection confirmed
the tumor histologic grade of T2N1M0 adenocarcinoma.
Discussion
Over the past four decades, the incidence of esophageal
adenocarcinoma has risen dramatically, particularly in
older white men [16]. Previous studies have documented
the association of esophageal cancer with the severity and
duration of gastroesophageal reflux [3]. The most impor-
tant risk factor for the development of esophageal adeno-
carcinoma, however, is the development of specialized
intestinal metaplasia in the lower esophagus (Barrett's
esophagus) [5]. It is recommended that patients with Bar-
rett's mucosa undergo periodic surveillance endoscopy
with systematic biopsies to detect the presence of cancer-
ous or pre-cancerous changes (dysplasia or neoplasia) [2].
In these patients, especially, Barrett's adenocarcinoma or
high-grade dysplasia is found at an early stage when it is
increasingly possible to undergo esophagectomy with cur-
ative intent [17].
After undergoing esophageal resection, the native squa-
mous mucosa of the cervical esophagus will be brought
into contact with the acid-secreting mucosa of the gastric
body. This reconstruction allows acid and duodenal juice
to reflux from the gastric conduit to the remaining cervical
esophagus. Reflux of gastric and duodenal content is an
important factor in the pathogenesis of Barrett's metapla-
sia, dysplasia and esophageal adenocarcinoma [18-20]. It
is well known that recurrent Barrett's glandular mucosa is
frequently found in the cervical esophagus after esopha-
geal resection [21-23]. Recently, Oberg et al performed
endoscopy, esophageal manometry and ambulatory pH
studies in 32 patients who had undergone esophagectomy
for a variety of diagnoses including 16 patients (50%)
with adenocarcinoma associated with Barrett's metaplasia
[24]. These studies were performed between 3–10 years
after the surgery and most of the patients (70%) were
receiving at least once daily proton pump inhibitor ther-
apy for chronic reflux symptoms. At endoscopy, Barrett's
glandular mucosa was histologically documented in 15
patients (47%) ranging in segment lengths from 0.5–4.0
cm. Importantly, recurrent Barrett's glandular mucosa was
significantly more likely to occur in patients with a preop-
erative diagnosis of Barrett's epithelium suggesting that
Table 1: Recurrent Barrett's Disease after Esophagectomy with Curative Intent 
Pre-operative diagnosis Sex Age F/u diagnosis Time to F/U Tx
Barrett's T3 N0 ACA F 58 Barrett's T2 N1 7 mos Surgery
Barrett's T3 N0 ACA F 64 Barrett's LGD 42 mos PPI
Barrett's T3 N0 ACA F 64 Barrett's LGD 42 mos PPI
Barrett's HGD M 64 Barrett's LGD 47 mos PPI
Barrett's HGD M 72 Barrett's Metaplasia 90 mos PPI
Barrett's T3 N0 ACA M 69 Barrett's T1 N0 18 mos Surgery
Barrett's T2 N0 ACA M 78 Barrett's metaplasia 17 mos PPI
Barrett's T2 N0 ACA M 80 BE+HGD 88 mos PDT
ACA = Adenocarcinoma
HGD = High-grade dysplasia
LGD = Low-grade dysplasia
PDT = Photodynamic therapy
PPI = Proton pump inhibitor medical therapyBMC Gastroenterology 2004, 4:18 http://www.biomedcentral.com/1471-230X/4/18
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the esophageal mucosa of these patients may be pathoge-
netically predisposed to develop metaplastic changes in
response to gastroesophageal reflux.
In the study of Oberg et al, despite the use of potent acid-
suppressing medications, severe esophageal acid exposure
was noted in most patients. Patients with recurrent Bar-
rett's epithelium were found to have significantly more
severe acid exposure that occurred predominantly in the
supine position [25]. There was also a direct correlation
between the length of the metaplastic segment and the
severity of acid reflux. Similar findings were reported by
da Rocha, et al., who studied 48 patients after esophagec-
tomy where 4 of these patents (8%) were found to have
pathological changes of Barrett's metaplasia in the cervical
esophageal stump [26]. In both of these studies, the
authors concluded that the finding of recurrent Barrett's
esophagus was related to reflux esophagitis that resulted
from the action of acid-peptic and biliary secretions.
These studies, however, did not detect dysplasia or neo-
plasia and did not address the issue of metachronous can-
cers and the role of endoscopic surveillance for these
patients.
Murata and colleagues recently reported the diagnosis of
metachronous squamous cell carcinomas in five of 253
patients (2%) who had undergone esophagectomy for
thoracic esophageal squamous cell carcinoma more than
two years previously. These superficial carcinomas (Tis or
T1) were detected at surveillance endoscopy and were
treated with endoscopic laser ablation, mucosal resection
or surgical resection. While squamous cell carcinomas are
not related to gastroesophageal reflux, this paper also sug-
gests that esophageal cancer patients (squamous or aden-
ocarcinoma) are predisposed to the development of
metachronous carcinomas in the remnant cervical
esophagus. This is consistent with DeMeester's experi-
mental model of Barrett's dysplasia and adenocarcinoma
occurring after complete gastrectomy with esophago-jeju-
nostomy and reflux of bile and digestive enzymes into the
cervical esophagus [27]. Also, it is likely that these patients
had other important risk factors, such as tobacco and alco-
hol use, that predispose to both squamous and adenocar-
cinomas [5].
Konishi et al reported finding an adenocarcinoma in Bar-
rett's esophagus following a total resection of the gastric
remnant in a 52-year-old man who had undergone distal
gastrectomy for gastric cancer nearly twenty years previ-
ously [28]. The Barrett's mucosa associated with the aden-
ocarcinoma contained high grade dysplasia supporting
the acquired theory of pathogenesis for Barrett's esopha-
gus that suggests that reflux esophagitis after gastrectomy
may result in the dysplasia-carcinoma sequence. In addi-
tion, Streitz et al retrospectively reviewed long-term survi-
vors after esophagectomy for adenocarcinoma [13]. With
a follow-up as long as 14 years, they found 4 patients who
subsequently were diagnosed with esophageal adenocar-
cinoma. However, the time period between the develop-
ment of the first and second tumors was not specified
making it not possible to determine if these were recurrent
tumors or new, metachronous lesions. Finally, Riben et al
have reported the development of a secondary Barrett's
adenocarcinoma in a patient who had 19 years previously
undergone esophagectomy for a stage IIb Barrett's adeno-
carcinoma [12].
These studies have demonstrated that the cervical esopha-
gus is exposed to high amounts of acid and refluxate
despite the use of proton inhibitor medications and often
in the absence of severe reflux symptoms. Although our
group of patients has been observed for only a median of
2 years after esophagectomy, our study confirms that the
development of metaplastic columnar mucosa in the cer-
vical esophagus is a common complication related to
reflux associated injury to the squamous epithelium. Fur-
ther, our findings suggest that this recurrent glandular
mucosa is unstable and predisposed to the development
of dysplasia and invasive carcinoma, as has already devel-
oped in most of patients.
The early detection of this recurrent disease remains
vitally important to preserve all possible treatment
options including surveillance endoscopy follow-up,
endoscopic ablation with porfimer sodium photody-
namic therapy, and if necessary repeat esophagus resec-
tion surgery. Our specific recommendations include
surveillance endoscopy every 6–12 months for patients
who have undergone "curative" esophagectomy for Bar-
rett's dysplasia or adenocarcinoma. In addition, we also
routinely recommend indefinite use of proton pump
inhibitors, regardless of symptom status, starting at twice
daily dosing and increasing as necessary to control reflux
symptoms and mucosal damage due to acid, bile and
digestive enzymes. Whether these drug doses should be
titrated based on ambulatory pH and impedance test
results remains to be determined. We have generally been
disappointed by prokinetic agents such as metoclopro-
mide in improving reflux symptoms in these patients. For
esophagectomy patients who develop recurrent Barrett's
metaplasia we recommend the use of COX-2 inhibitors or
aspirin chemoprevention to protect against the develop-
ment of metachronous Barrett's carcinoma. [29,30].
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